Efficacy of Primate Humoral Passive Transfer in a Murine Model of Pneumonic Plague Is Mouse Strain-Dependent

Table 3

A tabular summary of presented dose of aerosolised Y. pestis, passive immune therapy treatment, and MTD in BALB/c and Hsd:NIHS mice. The median time to death (MTD) was calculated using a Kaplan-Meier survival plot. N/D: not determined; over 50% of the mice survived to the end of these experiments; therefore an MTD could not be calculated.

Presented dose		Mouse strain	Study	Passive immune treatment	MTD
(CFU)	LD50
240	0.05	BALB/c	4	No treatment	N/D
3,000	0.6	BALB/c	4	No treatment	N/D
12,000	2.4	BALB/c	4	No treatment	3.7
62,026	12.4	BALB/c	1	Human reference serum	4.92
57,746	11.5	BALB/c	2	Human reference serum	4.18
69,390	13.9	BALB/c	3	Human reference serum	4.71
62,026	12.4	BALB/c	1	Human control negative serum	3.42
57,746	11.5	BALB/c	2	Human control negative serum	2.94
69,390	13.9	BALB/c	3	Human control negative serum	3.17
57,746	11.5	BALB/c	2	D35 40 𝜇g	3.94
57,746	11.5	BALB/c	2	D35 80 𝜇g	4.18
57,746	11.5	BALB/c	2	D35 120 𝜇g	4.18
69,390	13.9	BALB/c	3	D196 40 𝜇g	5.17
69,390	13.9	BALB/c	3	D196 80 𝜇g	5.17
69,390	13.9	BALB/c	3	D196 120 𝜇g	4.71
69,390	13.9	BALB/c	3	D365 40 𝜇g	4.33
69,390	13.9	BALB/c	3	D365 80 𝜇g	4.71
69,390	13.9	BALB/c	3	D365 120 𝜇g	4.71
240	0.05	Hsd:NIHS	4	No treatment	N/D
3,000	0.6	Hsd:NIHS	4	No treatment	3.46
12,000	2.4	Hsd:NIHS	4	No treatment	3.96
53,000	10.6	BALB/c	5	Human vaccine serum	5.48
53,000	10.6	BALB/c	5	Human control negative serum	3.48
53,000	10.6	Hsd:NIHS	5	Human vaccine serum	7.73
53,000	10.6	Hsd:NIHS	5	Human control negative serum	3.48
62,000	12	Hsd:NIHS	6	Human vaccine serum	7.75
62,000	12	Hsd:NIHS	6	Human control negative serum	3.25
62,000	12	Hsd:NIHS	6	Cynomolgus macaque vaccinated serum	N/D